A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
Recruiting · NCT07584226 · Registry updated 2026-07-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors | Advanced NRAS-Mutant Melanoma; Advanced NRAS-Mutant Solid Tumors; NRAS G12D; NRAS G12V; NRAS G13D; NRAS G13R; NRAS Mutation; NRAS Q61H; NRAS Q61K; NRAS Q61L; NRAS Q61R | Recruiting | Phase 1 | 2026-07-02 | NCT07584226 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Relay Therapeutics, Inc. | 4 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 300 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| NEXT Virginia | Fairfax | United States | 83 |
| Sarah Cannon Research Institute Oncology Partners | Nashville | United States | 12 |
| START Midwest, LLC | Grand Rapids | United States | 8 |
| University of California, Los Angeles | Los Angeles | United States | 142 |
| University of California, San Francisco | San Francisco | United States | 294 |
| University Of Colorado Hospital | Aurora | United States | 106 |